Children's Oncology Group 2023 blueprint for research: Adolescent and young adult oncology

Over the past few decades, 5‐year cancer survival has steadily improved for all adolescents and young adults (AYA, 15–39 years at diagnosis) combined. While encouraging, this progress simultaneously highlights a compelling need for improving survival in higher risk AYA subsets and for addressing hea...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2023-09, Vol.70 (S6), p.e30564-n/a
Main Authors: Roth, Michael E., Grimes, Allison C., Reed, Damon R., Weiss, Aaron R., Mittal, Nupur, Parsons, Susan K., Freyer, David R.
Format: Article
Language:English
Subjects:
Adolescent
adolescent and young adult oncology
Cancer
cancer care delivery
Cancer Care Facilities
Cancer therapies
Child
Clinical trials
Collaboration
Delivery of Health Care
Hematology
Humans
Malignancy
Medical Oncology
Medical prognosis
Neoplasms - therapy
Oncology
Pediatrics
Quality of Life
Survival
Toxicity
Young Adult
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over the past few decades, 5‐year cancer survival has steadily improved for all adolescents and young adults (AYA, 15–39 years at diagnosis) combined. While encouraging, this progress simultaneously highlights a compelling need for improving survival in higher risk AYA subsets and for addressing health outcomes and health‐related quality of life (HRQoL) among long‐term survivors. The Children's Oncology Group (COG), in collaboration with the National Cancer Institute (NCI) and the adult network groups within the NCI National Clinical Trials Network (NCTN), has developed a large and growing portfolio of therapeutic AYA cancer clinical trials to identify optimal treatment approaches for common AYA cancers. Additional initiatives, led by the COG AYA Oncology Discipline Committee for increasing collaboration between the COG and the adult network groups, optimizing AYA clinical trial enrollment, and standardizing the assessment of HRQoL, have been highly successful to date. Further, NCTN‐wide collaborations are currently underway focused on improving survival for AYA malignancies with poor prognosis and, through development of supportive care and care delivery trials, reducing the short‐ and long‐term toxicity caused by cancer treatment. Leveraging the research infrastructure within the NCTN and the NCI Community Oncology Research Program, the COG will continue to champion meaningful advancements in health and survival for AYAs with cancer.
ISSN:1545-5009
1545-5017
1545-5017
DOI:10.1002/pbc.30564